Profile data is unavailable for this security.
About the company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-36.05m
- Incorporated2011
- Employees24.00
- LocationTempest Therapeutics Inc2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE 94005United StatesUSA
- Phone+1 (415) 798-8589
- Fax+1 (302) 655-5049
- Websitehttps://www.tempesttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promis Neurosciences Inc | 0.00 | -29.28m | 28.09m | 6.00 | -- | 3.06 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -45.26m | 28.29m | 60.00 | -- | 0.9091 | -- | -- | -14.47 | -14.47 | 0.00 | 9.79 | 0.00 | -- | -- | 0.00 | -48.69 | -49.32 | -61.70 | -53.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.54 | -- | -54.23 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 28.70m | 26.00 | -- | 3.16 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -33.99m | 29.59m | 22.00 | -- | 0.4896 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| Outlook Therapeutics Inc | 1.51m | -62.42m | 29.74m | 17.00 | -- | -- | -- | 19.76 | -1.61 | -1.61 | 0.0432 | -0.5973 | 0.0635 | -- | -- | 88,548.23 | -263.36 | -240.08 | -- | -- | 70.78 | -- | -4,146.95 | -22,354.50 | 0.3067 | -200.54 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| Palatin Technologies Inc | 8.85m | -4.81m | 29.75m | 29.00 | -- | 40.89 | -- | 3.36 | -13.52 | -13.52 | 12.39 | 0.4073 | 1.47 | -- | -- | 305,087.90 | -79.90 | -79.95 | -- | -118.70 | 0.00 | 91.70 | -54.32 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Dyadic International Inc | 3.34m | -7.35m | 30.14m | 6.00 | -- | 11.56 | -- | 9.02 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 30.23m | 11.00 | -- | 24.40 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 30.29m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Lantern Pharma Inc | 0.00 | -18.92m | 30.31m | 24.00 | -- | 3.12 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 30.35m | 24.00 | -- | 1.61 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 30.90m | 8.00 | -- | 19.89 | -- | 41.59 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| VolitionRX Ltd | 1.47m | -22.88m | 31.03m | 85.00 | -- | -- | -- | 21.08 | -0.229 | -0.229 | 0.0147 | -0.316 | 0.1539 | -- | 4.74 | 17,317.88 | -241.07 | -122.29 | -- | -283.19 | -- | -- | -1,566.40 | -5,826.45 | -- | -15.03 | -- | -- | 59.10 | 135.30 | 23.65 | -- | 2.34 | -- |
| LAMY | 0.00 | 106.70k | 31.50m | -- | 32.80 | -- | 259.45 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.01m | 31.76m | 43.00 | -- | 1.34 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
Data as of Feb 10 2026. Currency figures normalised to Tempest Therapeutics Inc's reporting currency: US Dollar USD
15.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2025 | 492.22k | 9.99% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 140.14k | 2.84% |
| Geode Capital Management LLCas of 30 Sep 2025 | 41.02k | 0.83% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 39.07k | 0.79% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 22.25k | 0.45% |
| DRW Securities LLCas of 30 Sep 2025 | 18.83k | 0.38% |
| UBS Securities LLCas of 31 Dec 2025 | 17.54k | 0.36% |
| Belvedere Trading LLCas of 30 Sep 2025 | 5.33k | 0.11% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025 | 2.11k | 0.04% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 1.66k | 0.03% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
